In observance of Election Day, Goodwin’s US offices are closed on Tuesday, November 3. We encourage everyone in our community to do their civic duty and vote. The BMW blog will be back on Wednesday, November 4.
The post Election Day in the US appeared first on Big Molecule Watch.
Related Content
- Big Molecule WatchFebruary 5, 2026
Genentech/Hoffmann La-Roche and Shanghai Henlius Biotech/Organon Settle Pertuzumab BPCIA Case
- Big Molecule WatchFebruary 5, 2026
European Biologic and Biosimilar Updates
- Big Molecule WatchFebruary 4, 2026
FDA Issues Guidance on Modernizing Statistical Methods for Clinical Trials
- Big Molecule WatchJanuary 27, 2026
AbbVie and Novartis Announce Billion Dollar Licensing Deals for Oncology and Alzheimer’s Treatments
- Big Molecule WatchJanuary 21, 2026
Year in Review: Top Legal Developments of 2025
- Big Molecule WatchJanuary 13, 2026
Year in Review: Big Deals of 2025
- Big Molecule WatchJanuary 6, 2026
Celltrion and Sandoz Launch Their Aflibercept Biosimilars in Europe
- Big Molecule WatchDecember 29, 2025
Sun Pharma Launches ILUMYA® in India
- Awards and RankingsOctober 3, 2025
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Fourteenth Consecutive Year
- Awards and RankingsSeptember 9, 2024
Goodwin Named Venture Capital Firm of the Year, Hatch-Waxman Litigation Firm of the Year and Life Cycle Firm of the Year at the 2024 LMG Life Sciences Americas Awards
- Awards and RankingsSeptember 25, 2023
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Twelfth Consecutive Year
- Awards and RankingsOctober 4, 2022
LMG Recognizes Goodwin Lawyers and Practices for Excellence in Life Sciences
- Press ReleaseNovember 17, 2021
Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.
- Awards and RankingsOctober 26, 2021
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Tenth Consecutive Year
- Press ReleaseJune 28, 2021
Goodwin Adds Life Sciences and Healthcare Litigation Partner William Jackson
- EventsDecember 5, 2020
China's Patent Linkage System: Can Strategies that Work in the U.S. System Be Applied to China?